Dr. Niaz M. Haque, MD

Dr. Haque practices at Aspirus Stevens Point Surgery Center in Stevens Point, Wisconsin.

Dr. Haque's NPI, 1871783407, was assigned on July 30, 2007. Dr. Haque holds Wisconsin license 57472.

Dr. Haque's primary practice is Aspirus Stevens Point Surgery Center, at 5409 Vern Holmes Dr, Stevens Point, WI 54481. The practice phone is (715) 342-1015.

Dr. Haque's primary practice is Aspirus Stevens Point Surgery Center in Stevens Point, Wisconsin. Dr. Haque is also affiliated with Aspirus Stevens Point Hospital. The medical group on file is Aspirus Medical Group. Dmand AI also links Dr. Haque to 4 more hospitals, 5 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Haque practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Haque's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Haque's licenses on file in 2 states: Wisconsin and Mississippi.

CMS data shows 1,169 Medicare services from Dr. Haque across 7 procedure codes in 2024, for 249 Medicare patients. Medicare paid $53,335 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 249 Medicare patients who saw Dr. Haque in 2024. The largest group is 65 to 74, with 129 patients. 65% of them have high cholesterol, and 63% have high blood pressure. 14% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Haque's median patient age at 71, with 56% women.

In 2024, Dr. Haque wrote 1,466 Medicare Part D claims for 263 patients. 76% of them were for generic drugs. CMS names the drug for 1,207 of them, across 37 drugs with 11 or more claims each, at $3,791,119 in total drug cost. In 2023, CMS named 1,124 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Haque for performance year 2024, reported as part of a group. Dr. Haque accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Haque as offering telehealth.

Dmand AI links 1 paper to Dr. Haque. Dr. Haque's most frequent co-author is Brian C. Boulmay, MD.

Dmand AI links Dr. Haque to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Carcinoma, Intraductal, Noninfiltrating and Breast Carcinoma In Situ.

CMS Open Payments shows 72 general payments to Dr. Haque from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 42% of the total. Aveo Pharmaceuticals, Inc. paid the most, $1,385.